Literature DB >> 21860421

Oncogenic activation of FOXR1 by 11q23 intrachromosomal deletion-fusions in neuroblastoma.

E E Santo1, M E Ebus, J Koster, J H Schulte, A Lakeman, P van Sluis, J Vermeulen, D Gisselsson, I Øra, S Lindner, P G Buckley, R L Stallings, J Vandesompele, A Eggert, H N Caron, R Versteeg, J J Molenaar.   

Abstract

Neuroblastoma tumors frequently show loss of heterozygosity of chromosome 11q with a shortest region of overlap in the 11q23 region. These deletions are thought to cause inactivation of tumor suppressor genes leading to haploinsufficiency. Alternatively, micro-deletions could lead to gene fusion products that are tumor driving. To identify such events we analyzed a series of neuroblastomas by comparative genomic hybridization and single-nucleotide polymorphism arrays and integrated these data with Affymetrix mRNA profiling data with the bioinformatic tool R2 (http://r2.amc.nl). We identified three neuroblastoma samples with small interstitial deletions at 11q23, upstream of the forkhead-box R1 transcription factor (FOXR1). Genes at the proximal side of the deletion were fused to FOXR1, resulting in fusion transcripts of MLL-FOXR1 and PAFAH1B2-FOXR1. FOXR1 expression has only been detected in early embryogenesis. Affymetrix microarray analysis showed high FOXR1 mRNA expression exclusively in the neuroblastomas with micro-deletions and rare cases of other tumor types, including osteosarcoma cell line HOS. RNAi silencing of FOXR1 strongly inhibited proliferation of HOS cells and triggered apoptosis. Expression profiling of these cells and reporter assays suggested that FOXR1 is a negative regulator of fork-head box factor-mediated transcription. The neural crest stem cell line JoMa1 proliferates in culture conditional to activity of a MYC-ER transgene. Over-expression of the wild-type FOXR1 could functionally replace MYC and drive proliferation of JoMa1. We conclude that FOXR1 is recurrently activated in neuroblastoma by intrachromosomal deletion/fusion events, resulting in overexpression of fusion transcripts. Forkhead-box transcription factors have not been previously implicated in neuroblastoma pathogenesis. Furthermore, this is the first identification of intrachromosomal fusion genes in neuroblastoma.

Entities:  

Mesh:

Year:  2011        PMID: 21860421     DOI: 10.1038/onc.2011.344

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  29 in total

Review 1.  Therapeutic targets for neuroblastomas.

Authors:  Garrett M Brodeur; Radhika Iyer; Jamie L Croucher; Tiangang Zhuang; Mayumi Higashi; Venkatadri Kolla
Journal:  Expert Opin Ther Targets       Date:  2014-01-06       Impact factor: 6.902

Review 2.  Mechanisms of neuroblastoma regression.

Authors:  Garrett M Brodeur; Rochelle Bagatell
Journal:  Nat Rev Clin Oncol       Date:  2014-10-21       Impact factor: 66.675

3.  Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes.

Authors:  Jan J Molenaar; Jan Koster; Danny A Zwijnenburg; Peter van Sluis; Linda J Valentijn; Ida van der Ploeg; Mohamed Hamdi; Johan van Nes; Bart A Westerman; Jennemiek van Arkel; Marli E Ebus; Franciska Haneveld; Arjan Lakeman; Linda Schild; Piet Molenaar; Peter Stroeken; Max M van Noesel; Ingrid Ora; Evan E Santo; Huib N Caron; Ellen M Westerhout; Rogier Versteeg
Journal:  Nature       Date:  2012-02-22       Impact factor: 49.962

Review 4.  The emerging complexity of gene fusions in cancer.

Authors:  Fredrik Mertens; Bertil Johansson; Thoas Fioretos; Felix Mitelman
Journal:  Nat Rev Cancer       Date:  2015-06       Impact factor: 60.716

5.  New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs.

Authors:  Dominik Sturm; Brent A Orr; Umut H Toprak; Volker Hovestadt; David T W Jones; David Capper; Martin Sill; Ivo Buchhalter; Paul A Northcott; Irina Leis; Marina Ryzhova; Christian Koelsche; Elke Pfaff; Sariah J Allen; Gnanaprakash Balasubramanian; Barbara C Worst; Kristian W Pajtler; Sebastian Brabetz; Pascal D Johann; Felix Sahm; Jüri Reimand; Alan Mackay; Diana M Carvalho; Marc Remke; Joanna J Phillips; Arie Perry; Cynthia Cowdrey; Rachid Drissi; Maryam Fouladi; Felice Giangaspero; Maria Łastowska; Wiesława Grajkowska; Wolfram Scheurlen; Torsten Pietsch; Christian Hagel; Johannes Gojo; Daniela Lötsch; Walter Berger; Irene Slavc; Christine Haberler; Anne Jouvet; Stefan Holm; Silvia Hofer; Marco Prinz; Catherine Keohane; Iris Fried; Christian Mawrin; David Scheie; Bret C Mobley; Matthew J Schniederjan; Mariarita Santi; Anna M Buccoliero; Sonika Dahiya; Christof M Kramm; André O von Bueren; Katja von Hoff; Stefan Rutkowski; Christel Herold-Mende; Michael C Frühwald; Till Milde; Martin Hasselblatt; Pieter Wesseling; Jochen Rößler; Ulrich Schüller; Martin Ebinger; Jens Schittenhelm; Stephan Frank; Rainer Grobholz; Istvan Vajtai; Volkmar Hans; Reinhard Schneppenheim; Karel Zitterbart; V Peter Collins; Eleonora Aronica; Pascale Varlet; Stephanie Puget; Christelle Dufour; Jacques Grill; Dominique Figarella-Branger; Marietta Wolter; Martin U Schuhmann; Tarek Shalaby; Michael Grotzer; Timothy van Meter; Camelia-Maria Monoranu; Jörg Felsberg; Guido Reifenberger; Matija Snuderl; Lynn Ann Forrester; Jan Koster; Rogier Versteeg; Richard Volckmann; Peter van Sluis; Stephan Wolf; Tom Mikkelsen; Amar Gajjar; Kenneth Aldape; Andrew S Moore; Michael D Taylor; Chris Jones; Nada Jabado; Matthias A Karajannis; Roland Eils; Matthias Schlesner; Peter Lichter; Andreas von Deimling; Stefan M Pfister; David W Ellison; Andrey Korshunov; Marcel Kool
Journal:  Cell       Date:  2016-02-25       Impact factor: 41.582

Review 6.  Intergenically Spliced Chimeric RNAs in Cancer.

Authors:  Yuemeng Jia; Zhongqiu Xie; Hui Li
Journal:  Trends Cancer       Date:  2016-09

7.  Comparative genetic study of intratumoral heterogenous MYCN amplified neuroblastoma versus aggressive genetic profile neuroblastic tumors.

Authors:  A P Berbegall; E Villamón; M Piqueras; I Tadeo; A Djos; P F Ambros; T Martinsson; I M Ambros; A Cañete; V Castel; S Navarro; R Noguera
Journal:  Oncogene       Date:  2015-06-29       Impact factor: 9.867

8.  High expression of FOXR2 in breast cancer correlates with poor prognosis.

Authors:  Haiping Song; Wenshan He; Xiaoqing Huang; Huiqiong Zhang; Tao Huang
Journal:  Tumour Biol       Date:  2015-11-23

9.  Elevated AQP1 Expression Is Associated With Unfavorable Oncologic Outcome in Patients With Hilar Cholangiocarcinoma.

Authors:  Chunxiang Li; Xiaofu Li; Linfeng Wu; Zheng Jiang
Journal:  Technol Cancer Res Treat       Date:  2016-05-02

Review 10.  Interstitial Deletions Generating Fusion Genes.

Authors:  Ioannis Panagopoulos; Sverre Heim
Journal:  Cancer Genomics Proteomics       Date:  2021 May-Jun       Impact factor: 4.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.